NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 24 min 48 sec ago

Notice of Termination of PAR-16-138 "Cancer Research Education Grants Program to Promote Diversity - Research Experiences (R25)"

Fri, 2018-09-07 02:48
Notice NOT-CA-18-105 from the NIH Guide for Grants and Contracts

NIMHD Loan Repayment Program Technical Assistance Webinar

Fri, 2018-09-07 02:15
Notice NOT-MD-18-015 from the NIH Guide for Grants and Contracts

Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed)

Fri, 2018-09-07 02:05
Funding Opportunity RFA-DA-19-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HIV-associated neurological disorders (HAND) in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines.

Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R21-Clinical Trials Not Allowed)

Fri, 2018-09-07 02:05
Funding Opportunity RFA-DA-19-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HAND in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines.

Clarification: Fixed Amount Award Definition and Implementation for Clinical Trials

Thu, 2018-09-06 10:49
Notice NOT-OD-18-222 from the NIH Guide for Grants and Contracts

Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed)

Wed, 2018-09-05 12:29
Funding Opportunity PAR-18-911 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites P20 planning grant applications for developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, research experience, and research education. A major goal of the NCI P20 partnership programs is to provide support for investigators at ISUPS and Cancer Centers to conduct cancer research pilot projects and cancer research education program. The purpose of the pilot projects and education program is to allow awardees to obtain preliminary data that will lead to competitive grant applications for funding by the NIH/NCI and/or other Federal/Non-Federal agencies.

Notice of Changes to NICHD Acceptance of Diversity and Re-Entry Supplement Applications

Tue, 2018-09-04 02:50
Notice NOT-HD-18-018 from the NIH Guide for Grants and Contracts

Additional Awards Eligible for PA-18-906 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)

Tue, 2018-09-04 02:24
Notice NOT-OD-18-226 from the NIH Guide for Grants and Contracts

Notice of Pre-Application Webinar for the NIH Common Fund Acute to Chronic Pain Signatures Program

Tue, 2018-09-04 02:16
Notice NOT-RM-18-021 from the NIH Guide for Grants and Contracts

Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (U01) (Clinical Trial Required)

Fri, 2018-08-31 13:44
Funding Opportunity PAR-18-910 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that propose testing new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases in adult and pediatric populations. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Assets target will have a positive impact on the disease/condition.

Pages